Integral Diagnostics logo

IDX - Integral Diagnostics Share Price

A$4.8 -0.0  -0.6%

Last Trade - 26/02/21

Mid Cap
Market Cap £535.4m
Enterprise Value £670.8m
Revenue £176.9m
Position in Universe 294th / 1832
Unlock IDX Revenue
Relative Strength (%)
1m +6.15%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.14%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
151.4 168 180.1 189.7 232.4 275.6 348.4 370.9 +12.7%
+37.1 +90.7 -2.7 +4.7 +17.9 +0.8 +36.9 +8.33
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, IntegralDiagnostics Ltd revenues increased 30% to A$171.7M. Netincome increased 83% to A$19.9M. Revenues reflect Australiasegment increase of 26% to A$150.3M, New Zealand segmentincrease of 64% to A$21.5M. Dividend per share remainedflat at A$0.06. Basic Earnings per Share excludingExtraordinary Items increased from A$0.06 to A$0.10.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for IDX
Graphical History


IDX Revenue Unlock IDX Revenue

Net Income

IDX Net Income Unlock IDX Revenue

Normalised EPS

IDX Normalised EPS Unlock IDX Revenue

PE Ratio Range

IDX PE Ratio Range Unlock IDX Revenue

Dividend Yield Range

IDX Dividend Yield Range Unlock IDX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IDX EPS Forecasts Unlock IDX Revenue
Profile Summary

Integral Diagnostics Limited is an Australia-based healthcare services company. The Company is principally engaged in providing diagnostic imaging services to general practitioners, medical specialists and allied health professionals (referrers) and their patients. The Company offers its services using its three brands, which include Lake Imaging (Victoria), South Coast Radiology (Queensland) and Global Diagnostics (Western Australia). The Company's integrated network provides communication, which allows physicians to access images at any time from any location. Global Diagnostics provide patients in rural and regional communities its diagnostic imaging services. South Coast Radiology provides medical imaging services and patient care to Gold Coast and Tweed communities. The Company's subsidiaries include Lake Imaging Pty Ltd, Radploy Pty Ltd, Global Diagnostics (Australia) Pty Ltd, SCR Corporate Pty Ltd and RAD Corporate Pty Ltd.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated April 29, 2008
Public Since October 21, 2015
No. of Shareholders: 3,892
No. of Employees: n/a
Sector Healthcare
Industry Healthcare Providers & Services
Index S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 198,545,113
Free Float (0.0%)
Eligible for
IDX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IDX
Upcoming Events for IDX
Frequently Asked Questions for Integral Diagnostics
What is the Integral Diagnostics share price?

As of 26/02/21, shares in Integral Diagnostics are trading at A$4.8, giving the company a market capitalisation of £535.4m. This share price information is delayed by 15 minutes.

How has the Integral Diagnostics share price performed this year?

Shares in Integral Diagnostics are currently trading at A$4.8 and the price has moved by 21.83% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Integral Diagnostics price has moved by 18.26% over the past year.

What are the analyst and broker recommendations for Integral Diagnostics?

Of the analysts with advisory recommendations for Integral Diagnostics, there are there are currently 1 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Integral Diagnostics is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Integral Diagnostics next release its financial results?

Integral Diagnostics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Integral Diagnostics dividend yield?

The Integral Diagnostics dividend yield is 1.98% based on the trailing twelve month period.

Does Integral Diagnostics pay a dividend?

Last year, Integral Diagnostics paid a total dividend of 0.1, and it currently has a trailing dividend yield of 1.98%. Looking ahead, shares in Integral Diagnostics are due to go ex-dividend on 2021-03-01 and the next dividend pay date is 2021-04-06.

When does Integral Diagnostics next pay dividends?

Integral Diagnostics are due to go ex-dividend on 2021-03-01 and the next dividend pay date is 2021-04-06. The historic dividend yield on Integral Diagnostics shares is currently 1.98%.

How do I buy Integral Diagnostics shares?

To buy shares in Integral Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Integral Diagnostics?

Shares in Integral Diagnostics are currently trading at A$4.8, giving the company a market capitalisation of £535.4m.

Where are Integral Diagnostics shares listed? Where are Integral Diagnostics shares listed?

Here are the trading details for Integral Diagnostics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: IDX
What kind of share is Integral Diagnostics?

Based on an overall assessment of its quality, value and momentum, Integral Diagnostics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Integral Diagnostics share price forecast 2021?

Shares in Integral Diagnostics are currently priced at A$4.8. At that level they are trading at 3.5% discount to the analyst consensus target price of 0.00.

Analysts covering Integral Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of 0.192 for the next financial year.

How can I tell whether the Integral Diagnostics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Integral Diagnostics. Over the past six months, the relative strength of its shares against the market has been 1.64%. At the current price of A$4.8, shares in Integral Diagnostics are trading at 16.14% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Integral Diagnostics PE Ratio?

The Integral Diagnostics PE ratio based on its reported earnings over the past 12 months is 28.01. The shares are currently trading at A$4.8.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Integral Diagnostics?

Integral Diagnostics's management team is headed by:

Helen Kurincic - NEC
Chien Ping Ho - EDR
Rupert Harrington - NID
John Atkin - NID
Ian Kadish - CEO
Anne Lockwood - CFO
Raelene Murphy - NID
Kirsty Lally - SEC
Jacqueline Milne - EDR
Who are the major shareholders of Integral Diagnostics?

Here are the top five shareholders of Integral Diagnostics based on the size of their shareholding:

Viburnum Funds Pty Ltd Investment Advisor
Percentage owned: 6.64% (13.2m shares)
Perennial Value Management Ltd. Investment Advisor
Percentage owned: 6.05% (12.0m shares)
Yarra Funds Management Limited Investment Advisor
Percentage owned: 4.89% (9.71m shares)
Investors Mutual Limited Investment Advisor
Percentage owned: 4.87% (9.66m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 2.92% (5.80m shares)
Similar to IDX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.